Sentences with phrase «for disease in»

Identification of such genes could lead to carrier testing, a better understanding of the disease and long term better treatments for the disease in both dogs and humans.

We might want to blame «old age» for any disease in our senior dogs and look the other way for fear of what lies ahead.

Also, unless affected dogs live with cats and are exposed to cat litter, that doesn't account for the disease in dogs.

The overall prognosis for this disease in cats is highly variable depending on the clinical presentation of this disease.

This cause is close to her heart, as her family's dog Teddy had tested positive for the disease in his native Texas and was had to go through tiring treatment before making his way up north and into their home.

«People think they're making a difference and helping find a cure for disease in this lifetime, but the money's being parked in investment accounts.

And not only does fish consumption cut down on various risk factors for disease in both men and women, it's also incredibly important when it comes to having a healthy baby.

Early - life stressors are known to induce changes in gene expression that set the stage for disease in later life.30 Thus, unfortunately, exposure to mercury in either parent, even prior to conception, can affect the child's own genetic expression.

Recent FDA approval of front - line brentuximab vedotin with chemotherapy in patients with stage III / IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.

«If they do, then we have an excellent early marker for the disease in sheep that really matters to people.

Without really good markers for the disease's occurrence, for glaucoma progression, it's hard to develop new drugs and test them on people and determine whether or not those drugs are really good for the disease in a reasonable time period so developing biomarkers is going to be good both for glaucoma disease protection as well as for disease treatment.

We are developing in vivo models for the disease in the mouse, and in vitro models starting from human pluripotent stem cell lines.

A number of therapeutic efforts were employed for the disease in Asia and in Canada; however, no treatment of clear value was identified.

Notably, the level of mitochondrial DNA carryover during spindle transfer was found to be well below the threshold for disease in early embryos.

Genetic testing revealed no mutation that would account for the disease in both mother and daughter.

WHO estimates that about 240 million people worldwide are infected and more than 66.5 million were treated for the disease in 2015.

The findings suggest a new cause for the disease in humans.

One of the main challenges in finding a treatment for the disease in the future is the research and development of pharmacological therapies capable of activating the Crtc1 protein, with the aim of preventing, slowing down or reverting cognitive alterations in patients.

In one of the two studies, researchers found that germline EGFR T790M mutation results in a rare and unique lung cancer hereditary syndrome associated with an estimated 31 % risk for the disease in never - smokers.

Currently, there is no vaccine for the disease in humans.

The second criterion for the disease in the DSM - IV, an «intense fear of gaining weight or becoming fat,» has also been updated with the addition of «or persistent behavior that interferes with weight gain, even though at a significantly low weight.»

Patients who got it lived about 4 months longer, nearly 26 months total, than those who didn't — but that, say company executives, is still more than any other therapy has managed for this disease in a randomized trial.

Understanding a patient's prognosis can help doctors make treatment recommendations, which can be especially challenging for this disease in children.

This is congruent with the earliest osteological evidence for the disease in the archaeological records dated to 2000 BC from India.

Although a team led by Mahajan identified the gene responsible for the disease in 2012, a cure has yet to be developed.

You know, everything from cancer screening, all through to screening for disease in teeth for children.

It can be a direct cause of death but is also the most important single risk factor for disease in young children.

«This opens the possibility of developing more advanced diagnostic tools for diseases in which amyloid beta and tau are involved,» says Peter Nilsson, professor at the Department of Physics, Chemistry and Biology.

If we could hit the rewind button in our cells, we could open the door to all kinds of treatments for diseases in which cells have gone awry, ailments like Parkinson's disease and cancer.

Khine uses Shrinky Dinks — a favorite childhood toy that shrinks when you bake it in the oven — to build microfluidic chips to create affordable tests for diseases in developing countries.

Her presentation, Genomics - Based Personalized Healthcare, was number four of ten and explored how family history and genomic information can be used to develop personalized risk assessments and disease management plans for all diseases in the near future.

This is especially worrisome for diseases in which the genetic architecture of risk remains poorly understood.

Human skin cells have also been directly converted into neurons that can be used to study and find treatments for diseases in the brain, as well as liver cells and insulin - producing cells of the pancreas.

From the European Commission Research & Innovation website: «Study investigates aquatic parasites on fish», Researchers in the Czech Republic, Spain and the United Kingdom have successfully identified the cellular components and mechanisms that play a role in the proliferation of myxozoa, tiny aquatic parasites responsible for diseases in commercially valuable fish.

To evaluate the shared genetic etiology of type 2 diabetes (T2D) and coronary heart disease (CHD), we conducted a genome - wide, multi-ancestry study of genetic variation for both diseases in up to 265,678 subjects for T2D and 260,365 subjects for CHD.

Bottom Line: Phytic acids do not raise the risk for diseases in human populations, they lower them!

We also offer early detection blood profiles that look for diseases in the initial and most treatable stages.

Not exact matches

Novartis, Amgen, and BAI are trying to figure out whether or not an experimental treatment called CNP520 can delay Alzheimer's in the people at high risk for the disease — or prevent it altogether.

About 69 million employees in the U.S. say they miss work because of health problems every year, which reduces economic output by $ 260 billion per year, according to the Centers for Disease Control and Prevention.

Heart disease is the leading cause of death for men and women in the U.S. Every year over 700,000 Americans have a heart attack and half of those are fatal.

Like in 1989, when, two months after her husband's inauguration, she visited a residential home for babies infected with AIDS and publicly kissed a child and hugged an adult diagnosed with HIV, defying the conventional wisdom at the time that the disease was contagious.

«We're in a serious jam,» says Gerry Wright, director of the Michael DeGroote Institute for Infectious Disease Research at McMaster University.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

You have said that when grunge hit, it was like being a doctor specializing in a disease they just found a cure for.

The Bahamian - American physician and special adviser to the Carter Center is one of the key individuals responsible for the eradication of smallpox — a truly terrifying disease that in the 20th century alone killed as many as 300 million people.

Omada's digital therapeutics platform attempts to address disparate health care needs that can be particularly cumbersome for people at risk for chronic diseases like diabetes through a combination of data analytics, user engagement, and the broad goal of preventing these kinds of conditions from developing in the first place.

«If, for example, you follow 1,000 people who have a healthy lifestyle and 1,000 who don't,» he says, «without question there will be many more chronic diseases that develop in the 1,000 who don't have a healthy lifestyle.

«If we determine that our [treatment] can prevent or delay the onset of symptoms in healthy yet high - risk populations, this would represent a tremendous breakthrough for those that may face this debilitating disease.»

A study of increases or decreases in rates of a disease across years, calculated for groups of people, is called an ecologic study.

Founded in 2011, Innovent has built a portfolio of 16 potential products for treating cancer, autoimmune disorders and other diseases, and seven of those are in clinical development.